ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 9

Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus

Julian Torres Vazquez1, Alejandro Corzo Cruz 2, David Alberto Comoto Santacruz 2 and Omar Eloy Muñoz Monroy 1, 1Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Distrito Federal, Mexico, 2Universidad del Ejército y Fuerza Aérea/ Esc. Mil. Gdos. Snd., SEDENA, Mexico City, Mexico

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: chemokines, Lupus and biomarkers, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: Cytokines & Cell Trafficking Poster

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10 (IP-10) is a chemotactic chemokine for monocytes and T-Lymphocytes and has been studied as a potential biomarker to detect SLE activity. The clinical manifestations of the activity of this disease are difficult to assess for clinicians as there is no high sensitivity blood test available for diagnostic purposes. The aim of this study was to determine if SLE activity in our patients, evaluated using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), elevates the expression of IP-10 mRNA in leucocytes, measured as Fold Change using qRT-PCR.

Methods: We recruited SLE female patients, diagnosed according to SLICC 2012 classification criteria. The patients were classified in five groups (Control; n=30, Without Activity (WA); n=30, Mild Activity (Mi A); n=30, Moderate Activity (Mo A); n=30, Severe Activity (SA); n=30) according to SLEDAI results, subsequently blood samples were taken, labeled and transported with all preservation precautions to the Molecular Biology Laboratory where total RNA was extracted from leucocytes and quantified. Primers were designed to amplify a specific region in the exon 2 and 3 of the IP-10 gene and gene expression levels were determined using qRT-PCR. ANOVA test was used to compare the expression of IP-10 mRNA between groups and a Spearman test was used to correlate the SLEDAI with the IP-10 mRNA expression levels.

Results: Overexpression of IP-10 mRNA was observed in the SA group with a Fold Change of 3.0171 (p=0.02), SLEDAI correlates with an increased expression of IP-10 (R=0.9029); Group Mo A was omitted from the analysis due to inconsistent results probably caused by methodological errors.

Conclusion: IP-10 mRNA overexpression could be associated with Several Activity of SLE, quantification of IP-10 gene expression has potential as a biomarker to evaluate SLE activity. Complimentary techniques such as IP-10 protein quantification are suggested to confirm our observations.


Figure 1

qRT – PCR CTs analysis from IP-10 sequence amplification


Table 1

Overexpression of IP-10 in different groups


Figure 2

Correlation Activity of SLE with Fold Change R² = 0.9029 -WA = Without Activity, MA = Mild Activity, SA = Severe Activity-


Disclosure: J. Torres Vazquez, None; A. Corzo Cruz, None; D. Comoto Santacruz, None; O. Muñoz Monroy, None.

To cite this abstract in AMA style:

Torres Vazquez J, Corzo Cruz A, Comoto Santacruz D, Muñoz Monroy O. Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/chemokine-cxcl-10-gene-expression-as-a-potential-activity-biomarker-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chemokine-cxcl-10-gene-expression-as-a-potential-activity-biomarker-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology